Awan FT et al. International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL. Blood Adv 2022;6(18):5516-25. Abstract

Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2022;388(4):319-32. Abstract

Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program 2020;2020(1):336-45. Abstract

Mato AR et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389(1):33-44. Abstract

Robak T et al. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers 2022;14(3):771. Abstract

Thompson PA, Tam CS. Pirtobrutinib: A new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood 2023;141(26):3137-42. Abstract